Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Social Determinants of Health and Prevention of Cardiovascular Disease
Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Novo Nordisk Seeks FDA Approval for Higher-Dose Semaglutide 7.2 mg for Chronic Weight Management
Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.
Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes
Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.
Perimenopause Comes with "Feast-and-Famine" Swings in Hormone Levels, Says Gynecologist Bruce Dorr, MD
Dorr says symptoms can begin 10 years before cylces cease and explains why the hormonal feast and famine of perimenopause can go unrecognized.
Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes
Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.
Rising Youth Hypertension and Its Long-Term Impact on Coronary Disease: Two New Data Sets
A 2-fold rise in pediatric hypertension over 2 decades and new long-term imaging data signal a need to rethink how early clinicians act on elevated BP.
Dual GCG/GLP-1 Agonist Mazdutide 9 mg Produces 20% Weight Loss in Phase 3 Trial of Chinese Adults with Obesity
GLORY-2 participants showed continuous weight loss through 60 weeks with no plateau; mazdutide also improved multiple cardiometabolic markers.
Novo Nordisk Seeks FDA Approval for Higher-Dose Semaglutide 7.2 mg for Chronic Weight Management
Novo Nordisk submits an FDA application for semaglutide 7.2 mg for chronic weight management, supported by STEP UP trial data showing greater weight loss.
Weekly Dose Podcast: New Insights on Colonoscopy Adherence, rt-CGM in GDM, Semaglutide Effects, Parent Vaccine Views, and MI Causes
Topics include rideshare support for colonoscopy, rt-CGM benefits in GDM, semaglutide and food noise, vaccine views, and MI etiology.
Perimenopause Comes with "Feast-and-Famine" Swings in Hormone Levels, Says Gynecologist Bruce Dorr, MD
Dorr says symptoms can begin 10 years before cylces cease and explains why the hormonal feast and famine of perimenopause can go unrecognized.
Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes
Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.
Rising Youth Hypertension and Its Long-Term Impact on Coronary Disease: Two New Data Sets
A 2-fold rise in pediatric hypertension over 2 decades and new long-term imaging data signal a need to rethink how early clinicians act on elevated BP.
Dual GCG/GLP-1 Agonist Mazdutide 9 mg Produces 20% Weight Loss in Phase 3 Trial of Chinese Adults with Obesity
GLORY-2 participants showed continuous weight loss through 60 weeks with no plateau; mazdutide also improved multiple cardiometabolic markers.